Increased cellular glutathione and protection by bone marrow stromal cells account for the resistance of non-acute promylocytic leukemia acute myeloid leukemia cells to arsenic trioxide in vivo. [electronic resource]
Producer: 20060803Description: 521-9 p. digitalISSN:- 1042-8194
- Acute Disease
- Animals
- Antineoplastic Agents -- administration & dosage
- Arsenic Trioxide
- Arsenicals -- administration & dosage
- Bone Marrow Cells -- drug effects
- Buthionine Sulfoximine -- pharmacology
- Cell Count
- Cell Line, Tumor
- Coculture Techniques
- Disease Models, Animal
- Drug Resistance, Neoplasm -- drug effects
- Glutathione -- drug effects
- Humans
- Injections, Intraperitoneal
- Leukemia, Myeloid -- drug therapy
- Mice
- Mice, Inbred NOD
- Mice, SCID
- Oxides -- administration & dosage
- Stromal Cells -- drug effects
- Treatment Failure
No physical items for this record
Publication Type: Journal Article; Research Support, Non-U.S. Gov't
There are no comments on this title.
Log in to your account to post a comment.